The largest clinical program to date in patients with a potentially life-threatening blood cancer known as myelofibrosis (MF) has shown that a new therapeutic candidate, ruxolitinib, provided clinical benefits to patients compared to placebo and best available therapy. These benefits included reduction in spleen size and relief of debilitating symptoms...
Finasteride And Dutasteride Raise Risk Of High-Grade Prostate Cancer, FDA Informs
6/10/2011
Although finasteride and dutasteride lower overall risk of developing prostate cancer, they raise the chances of developing high-grade prostate cancer, a more serious form of the disease, the FDA (Food and Drug Administration) has announced. The Agency adds that the risk is low; but doctors need to be aware of this...
How Killer Immune Cells Avoid Killing Themselves
6/10/2011
After eight years of work, researchers have unearthed what has been a well-kept secret of our immune system's success. The findings published online on June 9th in Immunity, a Cell Press publication, offer an explanation for how specialized immune cells are able to kill infected or cancerous cells without killing themselves in the process...
ImmunoCellular Therapeutics Ltd. Expands Phase II Trial Of ICT-107
6/10/2011
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107...
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek® (99mTc-tilmanocept) met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures...
MDxHealth And Merck KGaA Extend Agreement For Use Of MGMT Assay In Brain Cancer Clinical Trials
6/10/2011
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized medicine, announced today that it will extend its agreement with Merck KGaA, Darmstadt, Germany, for use of MDxHealth's MGMT assay in Merck KGaA's brain cancer clinical trials. Financial terms of the agreement are not disclosed...
Since the first human cord blood transplant, performed in 1988, the safety and efficacy of umbilical cord blood transplantation in both children and adults with a variety of malignant and non-malignant diseases have been clearly established...
Remission Duration Of Lymphoma Doubled By New Therapy
6/10/2011
Clinical research has shown that recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab. These results are presented by Dr Hanneke Kluin-Nelemans at the 16th Congress of the European Hematology Association in London...
UCLA Researchers Given Early Access To Leading-Edge Technologies
6/10/2011
An agreement between UCLA and Roche will provide stem cell and cancer researchers with leading-edge technologies that will drive research capabilities and further the understanding of complex disease...
Study Confirms Safety, Cancer-Targeting Ability Of Nutrient In Broccoli, Other Vegetables
6/10/2011
Sulforaphane, one of the primary phytochemicals in broccoli and other cruciferous vegetables that helps them prevent cancer, has been shown for the first time to selectively target and kill cancer cells while leaving normal prostate cells healthy and unaffected...